According to detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial, trastuzumab deruxtecan demonstrated clinically meaningful tumor. Responses in previously treated patients with human epidermal growth factor receptor 2 mutant unresectable or metastatic nonsquamous non-small cell lung cancer.
According to detailed positive results from an interim analysis of the DESTINY-Lung02 phase 2 trial, trastuzumab deruxtecan demonstrated clinically meaningful tumor. Responses in previously treated patients with human epidermal growth factor receptor 2 mutant unresectable or metastatic nonsquamous non-small cell lung cancer.
